Related Experiment Video
Updated: Sep 17, 2025

Fetal Mouse Cardiovascular Imaging Using a High-frequency Ultrasound 30/45MHZ System
Published on: May 5, 2018
Cardiovascular manifestations of thalidomide embryopathy
Peter Franz Klein-Weigel1, Christina Ding-Greiner2
1Clinic for Angiology and Diabetology, Helios Hospital Berlin-Buch, Germany.
None:
More than 60 years after withdrawal of ConterganR (thalidomide) from the market, the issue is more relevant than ever for physicians specialised in vascular medicine and cardiology due to the age-related increased use of appropriate health services by those affected. We describe cardiovascular abnormalities of thalidomide embryopathy and point out clinically relevant features that may have a profound influence on the disease management. We also describe and discuss whether arteriosclerotic diseases and complications occur more frequently in those affected by thalidomide embryopathy than in the general population.
Related Concept Videos
Teratogenicity
Cardiovascular System Abnormal Findings I: Inspection and Palpation
Abnormal findings observed during an inspection
Endocarditis II: Clinical Features of Infective Endocarditis
Chronic Kidney Disease II: Clinical Manifestations
Coronary Artery Disease III: Clinical Manifestations
Cardiomyopathy II: Dilated Cardiomyopathy

